Overview

Project

Name

Area/Indication

Discovery

IND/CTA-Enabling

Clinical Phase 1

2AP01

AALVP-HPV

Prohylactic HPV

2AP02

AAVLP-HER2/Neu

Breast cancer

2AP03

AAVLP-IgE

Allergic diseases

2AP04

AAVLP-Aβ

Alzheimer's

2AP05

AAVLP-HSP70i

Autoimmune diseases

2AP06

AAVLP-HIV

Prophylactic HIV

2AP07

AAVLP-HNC

Head and neck cancer

Overview

Project

Name

Area/Indication

Status

2AP01

AALVP-HPV

Prohylactic HPV

100%

2AP02

AAVLP-HER2/Neu

Breast cancer

25%

2AP03

AAVLP-IgE

Allergic diseases

27%

2AP04

AAVLP-Aβ

Alzheimer's

24%

2AP05

AAVLP-HSP70i

Autoimmune diseases

27%

2AP06

AAVLP-HIV

Prophylactic HIV

10%

2AP07

AAVLP-HNC

Head and neck cancer

6%

2AP01

(status: Clinical Phase 1 finished)

A NEW HPV VACCINE FOR A GROWING MARKET

BLANK

Illustration of Human Papillomavirus with conserved L2 minor capsid protein in centres of L1 pentame

OVERVIEW:

  • Broader coverage than approved HPV vaccines
  • Formulated without adjuvants
  • Low production cost
  • First-in-human, clinical phase 1 trial finished
  • Information:

    The global market for prophylactic HPV vaccines is likely to grow rapidly as more and more countries expand national vaccination programs to include HPV vaccinations not only for girls but also for boys. In addition, it is now estimated that 60-70% of oropharyngeal cancers are caused by HPV virus infections, opening up a discussion on HPV vaccinations for adults too.
    More than 170 types of Human Papillomavirus have been fully sequenced and there are many more to be investigated. The most advanced approved HPV vaccine provides protection against nine HPV types. In pre-clinical tests, 2A Pharma’s HPV vaccine candidate, formulated without adjuvant, has been shown to provide protection against more than 20 HPV types (and we are still testing), including several that can cause both mucosal and cutaneous cancers in which existing vaccines do not protect against.

    READ MORE

    2AP02

    (status: Proof-of-principle)

    HER2 POSITIVE BREAST CANCER VACCINE CANDIDATE

    OVERVIEW:

  • Developed by screening 2A Pharma's mimotope library with Trastuzumab
  • Induces HER2 antibodies
  • Reduces tumour outgrowth in pre-clinical studies
  • Information:

    2A Pharma’s AAVLP-HER2/Neu peptide vaccine candidate has in laboratory tests been shown to induce antibodies specific to human HER2. In mouse models, regression of breast cancer tumors was observed after vaccination. In a proof-of-principle study carried out at the Medical University of Vienna, Austria, supported by Medigene AG, it was concluded that this vaccine strategy could help to establish active immunotherapy for breast-cancer patients.

    The Medical University of Vienna, Viral particles support prophylactic vaccination against breast cancer.

    READ MORE

    2AP03

    (status: Discovery/Proof-of-principle)

    AAVLP-IGE VACCINE

    OVERVIEW:

  • High anti-IgE auto-antibody response in non-human primates
  • Highly efficacious in blocking histamine release
  • Information:

    2A Pharma’s B-cell epitope vaccine candidate, AAVLP-IgE, has in laboratory tests with non-human primates been shown to be effective at inducing anti-IgE autoantibodies. This gives the potential for a vaccine with similar benefits to approved anti‐human immunoglobulin E (IgE) antibody treatments of, for example, asthma, nut allergy etc. Currently, the potential of a bivalent AAVLP-IgE vaccine is being investigated.

    READ MORE

    2AP04

    (status: Discovery)

    AAVLP-AMYLOID-BETA VACCINE

    OVERVIEW:

  • Induces A𝛽 specific antibodies recognizing monomeric and aggregated forms of human amyloid-beta
  • Decreases levels of soluble A𝛽 peptides and plaque load in brain of hAPP transgenic mice
  • BLANK

    Information:

    2A Pharma’s anti-amyloid-beta vaccine candidate, AAVLP-Amyloid-β, has in laboratory tests with transgenic mice over-expressing amyloid-beta mutant protein been shown to eliminate amyloid-beta soluble protein, a clear plaque from the cortex and significantly reduce plaque from the hippocampus.

    It is our hope that the drug candidate can be developed into a treatment for early-stage Alzheimer’s disease.

    READ MORE

    2AP05

    (status: Discovery)

    VACCINE AGAINST AUTOIMMUNE DISEASES

    OVERVIEW:

  • 2A Pharma’s anti-autoimmune vaccine candidate, is currently being tested in vitiligo models.
  • Aims to reverse inflammatory autoimmune response and restore pigmentation.
  • Planned to be tested as anti-transplant rejection vaccine.
  • Information:

    2A Pharma’s anti-autoimmune vaccine candidate has potential in a number of indications. The vaccine is currently being tested in a vitiligo model in collaboration with different partners.

    READ MORE

    2AP06

    (status: Discovery)

    PROPHYLACTIC HIV VACCINE CANDIDATE

    OVERVIEW:

  • Early stage project to develop a prophylactic HIV vaccine with superior protection.
  • Utilises 2A Pharma's AAVLP platform
  • Information:

    A number of prophylactic HIV vaccines are in mid-stage clinical trials, but published data indicates that vaccine candidates only provide around 50% protection against HIV infection. 2A Pharma is developing an alternative HIV vaccine which we believe will have superior characteristics. The vaccine candidate is initially being tested in collaboration with a European academic partner.

    READ MORE

    2AP07

    (status: Discovery)

    THERAPEUTIC HEAD AND NECK CANCER VACCINE

    OVERVIEW:

  • Early stage project to develop a therapeutic head and neck cancer vaccine.
  • Project partly funded by the EU Eurostars programme.
  • Collaboration with the Danish Technological Institute and DNASense.
  • Information:

    Head and neck cancers represent the sixth most common cancer worldwide, resulting in more than 350,000 deaths/year. Our AAVLP-HNC vaccine uses our mimotope selection technology and has the potential to minimize side effects, improve efficacy, and markedly reduce treatment costs. This will address an unmet medical need and benefit cancer patients as well as reduce healthcare expenses. In addition, our combination of advanced technologies will establish a versatile platform for developing further vaccines without knowing the antigen.

    READ MORE